Reduction of the postexcitatory cortical inhibition upon paired-click auditory stimulation in patients with Parkinson's disease.
OBJECTIVE
The aims of this study were: to investigate the postexcitatory inhibition of cortical evoked potentials on auditory paired-click stimulation in patients with Parkinson's disease (PD), to analyze the correlation of N1-P2 amplitude ratios (A2/A1) with latency of the P300 auditory event-related potential and to determine the influence of Levodopa intake on postexcitatory inhibition and P300 latency.


METHODS
The central (Cz) auditory evoked potentials were recorded in 61 patients with PD and 21 age-matched healthy subjects.


RESULTS
Postexcitatory inhibition in auditory cortex in PD was significantly reduced for interstimulus intervals 500, 700 and 900ms compared to control group. The degree of this reduction correlated positively with the potential P300 latency and negatively with the summary score of the Mini Mental State Examination (MMSE) which was used to study general cognitive status of the PD patients. Increase of the postexcitatory inhibition towards normal values and decrease of the P300 latency were observed (P<0.001) following the administration of Levodopa.


CONCLUSIONS
The findings of this study testify that inhibitory processes in auditory cortex are deficient in PD patients. The positive effect of Levodopa administration indicates an important role of dopamine-dependent neural mechanisms in modulation of inhibitory processes in the auditory sensory system.


CONCLUSIONS
The results show that inability of the brain to provide normal inhibition in PD is accompanied by the decline of cognitive indices, including parameters of evoked potential P300 that is related to fundamental aspects of cognitive functions, such as attention and memory.
Lukhanina
E P
EP
Department of Brain Physiology, A. A. Bogomoletz Institute of Physiology, 01024 Kiev 24, Ukraine. ink@geront.kiev.ua
Kapustina
M T
MT
Berezetskaya
N M
NM
Karaban
I N
IN
D000161:Acoustic Stimulation; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001303:Auditory Cortex / Q000187:drug effects / Q000503:physiopathology*; D018913:Event-Related Potentials, P300 / Q000187:drug effects / Q000502:physiology; D005072:Evoked Potentials, Auditory / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009433:Neural Inhibition / Q000187:drug effects / Q000502:physiology*; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*
D000978:Antiparkinson Agents; D007980:Levodopa